Pharmaceutical News

RSS

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda").

9 Nov 2009

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

9 Nov 2009

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.

9 Nov 2009

Daval International receives award for its anti-inflammatory agent AIMSPRO

Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

9 Nov 2009

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

EpiCept Corporation today announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.

9 Nov 2009

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

With his proposed health care reform plan, President Barack Obama has set his sights on cutting name-brand prescription drug costs by 50 percent for Medicare patients who fall into the "Part D" coverage gap, universally known as the "donut hole." Plan advocates rave about the potential cost-cutting and feel it's a promising start to health care reform.

7 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

Those biopharmaceutical companies that are able to incorporate innovative and flexible elements into their business models will be best positioned to survive healthcare reform and maintain attractive long-term returns, according to a white paper published today by Cowen Healthcare Royalty Partners, a global healthcare private equity firm, and Health Advances, a leading healthcare strategy firm.

7 Nov 2009

FDA extends review date of New Drug Application for GSK1838262/XP13512

GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.

7 Nov 2009

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7 Nov 2009

Poll examines the American public's response to H1N1 vaccine shortage

A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. The poll, which examines the American public's response to the H1N1 vaccine shortage, is the fifth in a series of surveys of public views concerning the H1N1 flu outbreak undertaken by the Harvard Opinion Research Program at HSPH.

7 Nov 2009

Rituximab drug potentially effective for treating Graves' eye disease, shows study

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.

7 Nov 2009

Calbiotech awarded a SBIR contract to develop analyte specific reagents for the diagnosis of Dengue virus

Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.

6 Nov 2009

Swine flu vaccine distribution to New York companies causes uproar

The distribution of swine flu vaccines to big name companies in New York has caused an uproar as people complain that children and health care workers should receive top priority. The New York Times reports: "New York City health officials have distributed small amounts of the swine flu vaccine to some major New York companies, including Wall Street banks like Goldman Sachs and Citigroup, even as shortages continue.

6 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

CVS investigated by FTC over business practices

"CVS Caremark Corp (CVS.N) has been the subject of a U.S. Federal Trade Commission investigation over some of its business practices since August, the company said on Thursday," Reuters reports. "Various groups have asked the government to look into CVS Caremark's practices since drugstore chain CVS bought pharmacy benefits management business Caremark Rx Inc in March 2007. They claim that changes to services in the pharmacy benefits business since the acquisition have led to higher prices, compromised quality of care and pushed patients to choose CVS drugstores over other pharmacies."

6 Nov 2009

55% of adult population in Greater Washington, DC say they will not get H1N1 flu vaccine, reveals poll results

Fifty-five percent of the adult population in the Greater Washington, DC region say they will not get the H1N1 flu vaccine, according to a new poll commissioned by the Greater Washington Board of Trade.

6 Nov 2009

H1N1 is now most dominant flu strain worldwide, WHO says

The H1N1 (swine flu) virus is now the dominant flu strain worldwide, the WHO reported Thursday, with the virus accounting for up to 70 percent of the flu viruses sampled in some countries, the Associated Press reports.

6 Nov 2009

Pharmaceutical News

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

Bend Research signs collaboration agreement with Vertex Pharmaceuticals

Daval International receives award for its anti-inflammatory agent AIMSPRO

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Locus Pharmaceuticals creates a new division, Ansaris

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

FDA extends review date of New Drug Application for GSK1838262/XP13512

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Poll examines the American public's response to H1N1 vaccine shortage

Rituximab drug potentially effective for treating Graves' eye disease, shows study

Calbiotech awarded a SBIR contract to develop analyte specific reagents for the diagnosis of Dengue virus

Swine flu vaccine distribution to New York companies causes uproar

Gonorrhea medication may help fight cancer

CVS investigated by FTC over business practices

55% of adult population in Greater Washington, DC say they will not get H1N1 flu vaccine, reveals poll results

H1N1 is now most dominant flu strain worldwide, WHO says

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News